ArticleMaterials today. Bio2026
Transient blood-brain barrier opening by focused ultrasound enhances ferumoxytol accumulation in glioblastoma.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanoparticle delivery to glioblastoma is limited by the blood-brain barrier (BBB), which restricts the transport of diagnostic and therapeutic agents into tumor tissue. Microbubble-mediated focused ultrasound (FUS) can transiently increase BBB permeability and enhance localized delivery of molecular probes and drugs. We tested whether MRI-guided microbubble-assisted FUS at 650 kHz enables spatially controlled and quantitatively measurable delivery of the FDA-approved ferumoxytol (FMX), an iron oxide nanoparticle formulation. Acoustic simulations were employed to quantify transcranial pressure fields and assess pressure-dependent BBB opening at a clinically relevant frequency and were experimentally validated in healthy mice. In mice bearing orthotopic U87 glioblastoma, MRI-guided microbubble-assisted FUS was focally applied to the tumor region, with intravenously administered Definity microbubbles mediating transient BBB opening, followed by intravenous injection of fluorescein-labeled FMX. Nanoparticle accumulation was quantified using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.